By Leigh Dayton, 16 June 2022
Cartherics is delighted to announce that Non-Executive Director Bryan Williams is one of the top 1000 scientists worldwide in the field of Genetics and Molecular Biology, according to Research.com, a prominent academic platform for scientists.
In the recently released edition its […]
By Leigh Dayton 9 June 2022
It’s official. As of this month, ovarian cancer campaigner Heather Hawkins takes up her role as an Advisory Board Member for Cartherics.
“It’s a privilege and an honour to be part of the Board,” she says. “And I’m looking forward to assisting […]
Dr Ian Nisbet Chief Operating Officer
Held in partnership with Harvard Stem Cell Institute, this virtual one-day investor and partner conference will explore stem cell therapeutics in the areas of regenerative medicine, oncology and emerging academic research. It will also showcase cutting-edge science, industry trends and the commercial potential of this innovative sector to an invited […]
Cartherics CEO, Alan Trounson
Alan Trounson is ranked among the world’s most prominent scientists
Cartherics CEO, Alan Trounson
In the following interview with ARMI Alan Trounson discusses the importance and challenges of translation
7th Innate Killer Summit (San Diego, California)
Cartherics Chief Development Officer, Dr Nicholas Boyd
The innate cell therapy field is exploding as novel research charges through the clinic, proving its potential as a safe, efficacious, and cost-effective treatment. From 30 March-1 April 2022 Pacific Daylight Time (PDT) industry experts will meet in San Diego, California to discuss […]
The 4th Allogeneic Cell Therapies Summit is the leading industry-dedicated meeting that considers pre-clinical development, translation, manufacturing, supply and storage of allogeneic cell therapies to improve the accessibility and efficacy of patient care worldwide.
400+ experts from pharma, biotech and leading academia are expected to attend in Boston, USA […]
Presentation at the Next Generation CAR-TCR Summit (London, UK)
Cartherics Chief Development Officer, Dr Nicholas Boyd
CAR-T immunotherapy has exploded over the last half a decade. It is now a billion-dollar market that is expanding rapidly with over 400+ new cell therapy trials in 2021 alone. But challenges still remain in solid tumours, toxicity management and manufacturing […]
Chief Development Officer, Dr Nicholas Boyd
Cell therapies have the potential to not only be life-saving but curative for a host of diseases. However, inherent limitations in autologous based CAR-T therapy face major roadblocks for mass adoption and therapeutic effects in solid tumour indications.
On Friday 28 January at 7:30 am AEDT Nicholas will discuss the design, […]
By Leigh Dayton, 20 January 2022
Pollyanna Goh – Polly to her friends, family and colleagues – is a specialist’s specialist. For the past decade she has worked in the field of induced pluripotent stem cells (iPSCs). She was such an […]
